Shanghai Fosun Pharmaceutical (600196.SH) subsidiary obtains approval from the US FDA for drug clinical trials.

Shanghai Fosun Pharmaceutical (600196.SH) announced that its controlling subsidiary, Shanghai Junji Health Technology Co., Ltd. (referred to as "Junji Health"), has received approval from the U.S. FDA (Food and Drug Administration) to conduct clinical trials for LBP-ShC4. Junji Health plans to conduct Phase I clinical trials for LBP-ShC4 once the conditions are met. LBP-ShC4 is a live biotherapeutic product developed independently by the group (company and its controlling subsidiaries/units) for the treatment of androgenetic alopecia (AGA). As of the date of this announcement (May 9, 2025), there are no live biotherapeutic products approved for the treatment of AGA (including monotherapy or combination therapy) worldwide.